4898 Federal Register / Vol. 87, No. 20 / Monday, January 31, 2022 / Notices 

members of the Committee (when 

additional voting members are added to 

the Committee to provide needed 

expertise, a quorum will be based on the 

combined total of regular and added 

members) or (2) to comprise a quorum 

when, because of unforeseen 

circumstances, a quorum is or will be 

lacking. Because of the size of the 

Committee and the variety in the types 

of issues that it will consider, FDA may, 

in connection with a particular 

committee meeting, specify a quorum 

that is less than a majority of the current 

voting members. The Agency’s 

regulations (21 CFR 14.22(d)) authorize 

a committee charter to specify quorum 

requirements. 

If functioning as a medical device 

panel, a non-voting representative of 

consumer interests and a non-voting 

representative of industry interests will 

be included in addition to the voting 

members. 

Further information regarding the 

most recent charter and other 

information can be found at https://

www.fda.gov/advisory-committees/ 

vaccines-and-related-biologicalproducts-advisory-committee/chartervaccines-and-related-biologicalproducts-advisory-committee or by 

contacting the Designated Federal 

Officer (see FOR FURTHER INFORMATION

CONTACT). In light of the fact that no 

change has been made to the committee 

name or description of duties, no 

amendment will be made to 21 CFR 

14.100. 

This document is issued under the 

Federal Advisory Committee Act (5 

U.S.C. app.). For general information 

related to FDA advisory committees, 

please visit us at https://www.fda.gov/ 

AdvisoryCommittees/default.htm. 

Dated: January 24, 2022. 

Lauren K. Roth, 

Associate Commissioner for Policy. 

[FR Doc. 2022–01858 Filed 1–28–22; 8:45 am] 

BILLING CODE 4164–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Health Resources and Services 

Administration 

Meeting of the Advisory Committee on 

Childhood Vaccines 

AGENCY: Health Resources and Services 

Administration (HRSA), Department of 

Health and Human Services (HHS). 

ACTION: Notice. 

SUMMARY: In accordance with the 

Federal Advisory Committee Act, this 

notice announces that the Advisory 

Commission on Childhood Vaccines 

(ACCV) will hold public meetings for 

the 2022 calendar year (CY). 

Information about the ACCV, agendas, 

and materials for these meetings can be 

found on the ACCV website at https:// 

www.hrsa.gov/advisory-committees/ 

vaccines/index.html. 

DATES: ACCV meetings will be held on: 

• March 3, 2022, 10:00 a.m. Eastern 

Time (ET)–4:00 p.m. ET; 

• June 2, 2022, 10:00 a.m. ET–4:00 

p.m. ET; 

• September 1, 2022, 10:00 a.m. ET– 

4:00 p.m. ET; and 

• December 1, 2022, 10:00 a.m. ET– 

4:00 p.m. ET. 

ADDRESSES: Meetings may be held inperson or virtually. For updates on how 

the meeting will be held, visit the ACCV 

website 30 business days before the 

meeting date, where instructions for 

joining meetings either in-person or 

remotely will be posted. In-person 

ACCV meetings will be held at 5600 

Fishers Lane, Rockville, Maryland 

20857. For meeting information 

updates, go to the ACCV website 

meeting page at https://www.hrsa.gov/ 

advisory-committees/vaccines/ 

meetings.html. 

FOR FURTHER INFORMATION CONTACT: 

Annie Herzog, Division of Injury 

Compensation Programs, HRSA, 5600 

Fishers Lane, 08N186B, Rockville, 

Maryland 20857; 301–443–6634; or 

ACCV@HRSA.gov. 

SUPPLEMENTARY INFORMATION: The ACCV 

provides advice and recommendations 

to the Secretary of HHS on policy, 

program development, and other issues 

related to the implementation of the 

National Vaccine Injury Compensation 

Program and concerning other matters 

as described under section 2119 of the 

Public Health Service Act (42 U.S.C. 

300aa–19). 

Since priorities dictate meeting times, 

be advised that times and agenda items 

are subject to change. Refer to the ACCV 

website listed above for any meeting 

updates that may occur. For CY 2022 

meetings, agenda items may include, 

but are not limited to: Updates from the 

Division of Injury Compensation 

Programs, Department of Justice, Office 

of Infectious Disease and HIV/AIDS 

Policy (HHS), Immunization Safety 

Office (Centers for Disease Control and 

Prevention), National Institute of 

Allergy and Infectious Diseases 

(National Institutes of Health) and 

Center for Biologics, Evaluation and 

Research (Food and Drug 

Administration). Refer to the ACCV 

website listed above for all current and 

updated information concerning the CY 

2022 ACCV meetings, including draft 

agendas and meeting materials posted 5 

calendar days before the meeting(s). 

Members of the public will have the 

opportunity to provide comments. 

Public participants may submit written 

statements in advance of the scheduled 

meeting(s). Oral comments will be 

honored in the requested order and may 

be limited as time allows. Requests to 

submit a written statement or make oral 

comments to ACCV should be sent to 

Annie Herzog using the contact 

information above at least 5 business 

days before the meeting date(s). 

Individuals who need special 

assistance or another reasonable 

accommodation should notify Annie 

Herzog using the contact information 

listed above at least 10 business days 

before the meeting(s) they wish to 

attend. If in-person meetings occur, they 

will be held in a federal government 

building and attendees must go through 

a security check to enter the building. 

Non-U.S. Citizen attendees must notify 

HRSA of their planned attendance at 

least 20 business days before the 

meeting to facilitate their entry into the 

building. All attendees are required to 

present government-issued 

identification before entry. 

Maria G. Button, 

Director, Executive Secretariat. 

[FR Doc. 2022–01848 Filed 1–28–22; 8:45 am] 

BILLING CODE 4165–15–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center for Scientific Review; Notice of 

Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Biobehavioral and 

Behavioral Processes Integrated Review 

Group; Biobehavioral Mechanisms of 

Emotion, Stress and Health Study Section. 

Date: February 24–25, 2022. 

Time: 10:00 a.m. to 8:00 p.m. 


khammond on DSKJM1Z7X2PROD with NOTICES